BioMed X GmbH

BioMed X - Merck collaboration in the field of selective kinase inhibitors reaches major milestone

Heidelberg (ots) - BioMed X Innovation Center and Merck announced today that their collaboration, under which Merck has acquired all generated research and development results in the field of selective kinase inhibitors from BioMed X, has reached a major milestone. In addition, the respective research group at BioMed X is now offering a unique set of bio- and cheminformatics services to research institutes and companies world-wide.

BioMed X and Merck have jointly developed a unique innovation model which combines a global crowdsourcing approach with local incubation of the brightest ideas and research talents. Merck became the first partner of BioMed X in 2013. At the BioMed X Innovation Center on the life science campus of the University of Heidelberg, BioMed X and Merck jointly set up three new research groups. One of them, led by Simone Fulle, has developed novel bioinformatics tools that enable the design of highly selective inhibitors of kinases, a relatively large protein family which plays an important role in many human diseases such as cancer and chronic inflammation.

"We are very proud of this early proof of concept of our new innovation model", said Christian Tidona, founder and Managing Director of BioMed X. "Now it is evident that our unique research and development approach delivers significant value to our pharma partners."


BioMed X Innovation Center
Im Neuenheimer Feld 583
69120 Heidelberg, Germany

Eva-Maria Gottmann
Director of Marketing
Phone: +49 6221 426 11 10
Original-Content von: BioMed X GmbH, übermittelt durch news aktuell

Themen in dieser Meldung

Das könnte Sie auch interessieren: